Research areas



The SGC Frankfurt is focused on the development and rational design of selective inhibitors (chemical probes) targeting key signaling molecules and their use for the validation of new targets. Chemical probes are cell-permeable small-molecule modulators of protein function with stringent quality criteria on potency and selectivity. (Read more)


In the framework of the IMI JU2 initiative EUbOPEN, SGC Frankfurt aims to assemble a highly annotated chemogenomics library (CGL). Chemogenomic compounds are pharmacological modulators which interact with products of the genome and alter their biological function (Read more). In contrast to chemical probes which have to fulfil stringent criteria on potency and selectivity, the potency of chemogenomic compounds is often not sufficient to be chemical probes. Thus chemogenomics compounds allow a wider spectrum of targets or target family directed chemogenomic sets.


The research teams focus on the following key research areas:

  • Kinases: Strategies for the development of highly specific inhibitors will be focused on a) allosteric inhibitors and inhibitors targeting unique active site pockets. This approach allows us to interrogate catalytic as well as scaffolding functions of kinases exploring also catalytically inactive or weakly active pseudokinases as drug targets; b) We are also developing covalent kinase inhibitors by targeting cysteines in the proximity of the ATP binding pocket using electrophilic groups and c) we are exploring improved shape compatibility using macrocycles to generate novel and more specific kinase inhibitors targeting the active (type I) and inactive states (type II).
  • Inhibitors that target key enzymes and protein-protein interactions such as bromodomains modulating chromatin and epigenetic mechanisms.
  • Development and characterization of chemical probes targeting the ubiquitin system.
  • Open science chemical probes for the research community.